Related Experiment Video
Updated: May 11, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer
Félicie Cottard1, Irène Asmane, Eva Erdmann
1INSERM U1113, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Abstract:
Androgen receptor (AR) signaling pathway remains the foremost target of novel therapeutics for castration-resistant prostate cancer (CRPC). However, the expression of constitutively active AR variants lacking the carboxy-terminal region in CRPC may lead to therapy inefficacy. These AR variants are supposed to support PCa cell growth in an androgen-depleted environment, but their mode of action still remains unresolved. Moreover, recent studies indicate that constitutively active AR variants are expressed in primary prostate tumors and may contribute to tumor progression. The aim of this study was to investigate the impact of constitutively active AR variants on the expression of tumor progression markers. N-cadherin expression was analyzed in LNCaP cells overexpressing the wild type AR or a constitutively active AR variant by qRT-PCR, Western blot and immunofluorescence. We showed here for the first time that N-cadherin expression was increased in the presence of constitutively active AR variants. These results were confirmed in C4-2B cells overexpressing these AR variants. Although N-cadherin expression is often associated with a downregulation of E-cadherin, this phenomenon was not observed in our model. Nevertheless, in addition to the increased expression of N-cadherin, an upregulation of other mesenchymal markers expression such as VIMENTIN, SNAIL and ZEB1 was observed in the presence of constitutively active variants. In conclusion, our findings highlight novel consequences of constitutively active AR variants on the regulation of mesenchymal markers in prostate cancer.
Insights
Constitutively active androgen receptor (AR) variants promote prostate cancer progression by increasing N-cadherin and other mesenchymal markers. This finding offers new insights into castration-resistant prostate cancer (CRPC) therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- The androgen receptor (AR) signaling pathway is a key therapeutic target for castration-resistant prostate cancer (CRPC).
- Constitutively active AR variants, lacking the carboxy-terminal region, are implicated in CRPC and may drive tumor progression despite androgen depletion.
- The precise mechanisms by which these AR variants promote cancer progression remain unclear.
Purpose of the Study:
- To investigate the impact of constitutively active AR variants on the expression of tumor progression markers in prostate cancer.
- To elucidate the role of these variants in the context of castration-resistant prostate cancer.
Main Methods:
- Overexpression of wild-type AR and constitutively active AR variants in LNCaP and C4-2B prostate cancer cell lines.
- Analysis of N-cadherin, Vimentin, SNAIL, and ZEB1 expression using qRT-PCR, Western blot, and immunofluorescence.
Main Results:
- Constitutively active AR variants significantly increased N-cadherin expression in prostate cancer cells.
- Upregulation of other mesenchymal markers, including VIMENTIN, SNAIL, and ZEB1, was observed in the presence of these AR variants.
- Downregulation of E-cadherin was not observed, despite the increase in N-cadherin.
Conclusions:
- Constitutively active AR variants play a significant role in regulating mesenchymal markers, suggesting a novel mechanism for prostate cancer progression.
- These findings highlight potential new therapeutic strategies targeting AR variants in CRPC.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Mitogens and the Cell Cycle
Master Transcription Regulators
MAPK Signaling Cascades
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...

